The latest update is out from OncoCyte ( ($OCX) ). Oncocyte Corporation has announced a private sale of over 3.4 million shares at $2.948 each to accredited investors, with the
The latest update is out from OncoCyte ( ($OCX) ). Oncocyte Corporation has announced a private sale of over 3.4 million shares at $2.948 each to accredited investors, with the
In a report released yesterday, Mark Massaro from BTIG reiterated a Hold rating on OncoCyte (OCX – Research Report). The company’s shares closed yesterday at $3.15. According to TipRanks, Massaro
Oncocyte’s VitaGraft™ Kidney Used to Monitor Effect of Daratumumab on Anti-body Mediated Rejection in New Case Series Study
OncoCyte (OCX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Michael Matson from Needham maintained a Buy rating on the stock and
OncoCyte (OCX) has shared an update. Oncocyte Corporation has initiated a sales agreement with Needham & Company, LLC to potentially sell up to $7.5 million of its common stock at